Evidence map›Paper›PMID 38542363›Full record

ReviewInternational journal of molecular sciences2024

Functional Consequences of CFTR Interactions in Cystic Fibrosis.

Yashaswini Ramananda, Anjaparavanda P Naren, Kavisha Arora

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Nucleotide Variant in theJournal of clinical medicine · 2026
    Article
  8. Article
  9. Role of theInternational journal of molecular sciences · 2025
    Article
  10. mRNA Isoforms and Variants in Health and Disease.International journal of molecular sciences · 2025
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis.International journal of molecular sciences · 2024
    Review
  16. Article
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Yashaswini RamanandaDepartment of Pediatrics, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Anjaparavanda P NarenDepartment of Pediatrics, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Kavisha AroraDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Cedars-Sinai Medical Center · USCincinnati Children's Hospital Medical Center · US

Funding

Pilot and Feasibility ProgramP30DK117467 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Raouf S. Amin · 2018 to 2026
$11.4M
Inhibition of an apical cAMP transporter (MRP4) in the gut induces diarrheaR01DK080834 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Anjaparavanda P Naren · 2009 to 2026
$6.8M
Investigating of the Mechanisms of Action of CFTR Correctors in RescuingDelta F508-CFTRR01HL147351 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI NAREN, ANJAPARAVANDA P · 2020 to 2023
$1.7M
NHLBI NIH HHS R01 HL147351NIDDK NIH HHS P30 DK117467NIDDK NIH HHS R01 DK080834NIH HHS DK080834NIH HHS P30-DK117467NIH HHS R01HL147351
6 · The paper itself

Abstract

Cystic fibrosis (CF) is a fatal autosomal recessive disorder caused by the loss of function mutations within a single gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). CFTR is a chloride channel that regulates ion and fluid transport across various epithelia. The discovery of CFTR as the CF gene and its cloning in 1989, coupled with extensive research that went into the understanding of the underlying biological mechanisms of CF, have led to the development of revolutionary therapies in CF that we see today. The highly effective modulator therapies have increased the survival rates of CF patients and shifted the epidemiological landscape and disease prognosis. However, the differential effect of modulators among CF patients and the presence of non-responders and ineligible patients underscore the need to develop specialized and customized therapies for a significant number of patients. Recent advances in the understanding of the CFTR structure, its expression, and defined cellular compositions will aid in developing more precise therapies. As the lifespan of CF patients continues to increase, it is becoming critical to clinically address the extra-pulmonary manifestations of CF disease to improve the quality of life of the patients. In-depth analysis of the molecular signature of different CF organs at the transcriptional and post-transcriptional levels is rapidly advancing and will help address the etiological causes and variability of CF among patients and develop precision medicine in CF. In this review, we will provide an overview of CF disease, leading to the discovery and characterization of CFTR and the development of CFTR modulators. The later sections of the review will delve into the key findings derived from single-molecule and single-cell-level analyses of CFTR, followed by an exploration of disease-relevant protein complexes of CFTR that may ultimately define the etiological course of CF disease.

Indexed as

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorHumansMutationPrecision MedicineQuality of LifeSignal TransductionCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorCFTR interactorsCFTR modulatorscystic fibrosisCystic Fibrosis Transmembrane Conductance Regulatorsingle-cell analyses of CFTR

Identifiers

PMID38542363
PMCPMC10970640
OpenAlexW4392921138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.